EP0232262A1 - Tryptophan producing microorganism - Google Patents

Tryptophan producing microorganism

Info

Publication number
EP0232262A1
EP0232262A1 EP85904319A EP85904319A EP0232262A1 EP 0232262 A1 EP0232262 A1 EP 0232262A1 EP 85904319 A EP85904319 A EP 85904319A EP 85904319 A EP85904319 A EP 85904319A EP 0232262 A1 EP0232262 A1 EP 0232262A1
Authority
EP
European Patent Office
Prior art keywords
tryptophan
host
plasmid
control
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP85904319A
Other languages
German (de)
French (fr)
Other versions
EP0232262A4 (en
Inventor
Desmond Mascarenhas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stauffer Chemical Co
Original Assignee
Stauffer Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stauffer Chemical Co filed Critical Stauffer Chemical Co
Publication of EP0232262A1 publication Critical patent/EP0232262A1/en
Publication of EP0232262A4 publication Critical patent/EP0232262A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/04Alpha- or beta- amino acids
    • C12P13/22Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • C12P13/227Tryptophan

Definitions

  • the present invention relates to Escherichia coli (E. coli) microorganisns carrying plasmid borne genetic information for the prcduction of L-tryptophan and methods for prcducing and increasing the fermentative production of L-tryptophan.
  • Escherichia coli E. coli
  • Tryptophan is an amino acid that is an essential component in animal nutrition. Its fermentative production by microorganisns from inexpensive carbohydrate substrates is highly desirable.
  • Microorganisms used to this end include Brevibacterium (U.S. Pat. 3,700,539), Enterobacter (U.S. Pat. 4,439,627), Bacillus, particularly Bacillus subtilis [using anthranilate and carbon, nitrogen and mineral sources (U.S. Pat. 4,363,875; Japanese Patent Application J58017190, 1,3-5A, and European Patent Application EP 81-107)] and Corynebacterium glutamicum ATCC 21851.
  • E. coli strains described therein carry a specific plasmid having thereon genes of the wild type tryptophan operon ( trpA-E ) with a wild type or temperature sensitive tryptophan repressor gene (trpR or trpRts, respectively) for control of tryptophan biosynthesis.
  • trpA-E wild type tryptophan operon
  • trpR or trpRts wild type or temperature sensitive tryptophan repressor gene
  • Such plasmid or multicopy plasmid may also carry a Serine B gene (SerB).
  • the present invention is intended to meet the persistent need for inexpensively produced tryptophan by providing a bacterial host microorganism, of the genus Escherichia, deficient in the enzyme tryptophanase carrying plaanid borne information for the production of tryptophan wherein said information is divided between at least two plaanids.
  • Another object of the invention is to provide a method for producing tryptophan by culturing the above-mentioned bacterial host and plaanids therein in a culture medium and recovering L-tryptophan from the fermented culture medium.
  • Still another object of the invention is to provide inexpensively produced tryptophan by providing a bacterial host microorganian of the genus Escherichia deficient in the enzyme tryptophanase carrying plaanid borne genetic information for the prcduction of tryptophan wherein a portion of said information for the production of tryptophan is under lac operator/promoter control.
  • Yet another object of the invention is to provide a method for producing tryptophan by culturing the above-mentioned bacterial host with plaanid borne information for the prcduction of tryptophan, a portion of said information being under lac operator/promoter control in a culture medium and recovering tryptophan from the fermented culture median.
  • a still further object of the invention is to increase the production of tryptophan by a bacterial host of the genus Escherichia deficient in the enzyme tryptophanase by transforming said host with plasmid borne information to control tryptophan production divided between at least two plaanids; or by transforming the bacterial host as described with plaanid borne information to control tryptophan production a portion of said information being under lac promoter/operator control, or by transforming said host as described with plasmid borne information to control tryptophan prcduction divided between at least two plaanids, a portion of said information to control tryptophan prcduction being under lac operator/promoter control.
  • the plaanids used in this invention may be E. coli plaanids or plaanids capable of replicating in E. coli. If the information to control tryptophan prcduction is distributed on more than one plasmid, it is desirable to use plaanids that are replication compatible. Thus, for example, when the information to control tryptophan prcduction is distributed on two plaanids, plaanids having a ColE1 origin of replication may be used to carry part of the information and plaanids having a p15A origin of replication may be used to carry another part of the information.
  • Useful in the plasmid constructions of the type described in the invention are the following: ColEl, pSC101, pSF2124, pMB3, pMB9, pACYC184, pACYC177, pCK1, R6X, pBR312, pBR313, pBR317, OBR318, pBR320, PSR321, pBR322, pBR333, pBR341, pBR345, pBR350, pBR351, pML2, pML21, ColElaD, RSF1010, pVH51, pVh151, pVH153 (Recombinant Molecules: Impact on Science and Society: Beers, R.F., and Bassett, E.G., eds.
  • the preferred plasmids are the multicopy plaanids of the type of pBR and its derivatives, ColEl and its derivatives, p15A and its derivatives, pHH509 and its derivatives and pSC101 and its derivatives.
  • At least one of the plaanids may furthermore be desirable for at least one of the plaanids to contain a par locus (Meacock, P.A. and Cohen, S.N., Cell, 20:529-542 (1980)). If the information to control tryptophan production is distributed anong more than two plaanids it is preferred that all plaanids be replication compatible with each other, by constructing them such that they each carry different origins of replication.
  • the plaanids used in the invention are single copy (stringent) or multicopy (relaxed) plasmids. Because tryptophan yields can be increased by increasing the copy nunber of plaanids carrying information multicopy plaanids are preferred. Although multicopy plaanids can be frequently lost from the host cell, i.e., are unstable, plasmid copy nunber may be maintained by constructing the plasmids such that determinants of antibiotic resistance are carried thereon. By adding antibiotics to the culture medium, microorganisms that lose plasmids are eliminated or fall to insignificant nunbers, depending on the mode of antibiotic action.
  • Plasmids used in this invention bear genetic information to control tryptophan production.
  • the term "information to control tryptophan production" according to the invention includes:
  • the controlling elements used in the invention are nucleotide sequences derived from the lactose operon and include the lac operon promoter/ operator and lac repressor sequences. According to the invention, various portions of 1 and 2 are under lac control and produce significant amounts of functional gene products only in the presence of lactose. According to the invention it is preferred that tandem lac operator/promoters are used to achieve greater levels of gene expression than are possible with a single lac promoter.
  • the genetic information to control tryptophan prcduction according to the invention comprises a large n ⁇ nber of DNA sequences ceding for genes and regulatory sequences thereof, which are plaanid borne.
  • the terms "gene” or “genes” as used herein are meant to encompass a DNA sequence ceding for an active product of the gene.
  • DNA sequences ceding for an active gene product are genes within this definition even though the particular DNA sequence may not include the complete structural gene for the active product of the gene.
  • the genetic information to control tryptophan production on plaanids it is convenient to divide the genetic information between at least two plasmids.
  • the elenents can be positioned relative to information they control and their gene products can be produced in sufficient concentration to insure that the information controlling biosynthesis of the common aromatic amino acid precursors, information controlling biosynthesis of tryptophan from chorismic acid and/or information controlling biosynthesis of serine are expressed under optimum conditions and at the desired time in a fermentation cycle.
  • the plaanid-borne information to control tryptophan prcduction is divided between at least two plasmids.
  • Figure 1 and Figure 2 are schematic drawings of the preferred embediments of the plaanids carrying information to control tryptophan production according to the invention.
  • Fragment Numbers 1-11 of Table 1 read in conjunction with Figure 1 identifying each restriction endonuclease segment of each plaanid.
  • Fragment Numbers 12-14 identify the restriction endonuclease segments of the plaanid within Figure 2.
  • Table 1 further identifies each segment by approximate size in kilobases (kb), restriction nuclease ends of each fragment, genes/loci on the fragment, sequence coordinates if known, and journal reference for each known sequence coordinate.
  • the depicted segment sizes in Figure 1 are only approximately proportional to the size of the complete plaanid as shown.
  • coli host strains may be transformed by growing them to an optical density of about 0.6 at 600 nanometers in liquid median, chilling the cell suspension on ice for approximately 5 minutes, harvesting the cells by centrifugation, washing the cells in chilled 10 mM MgCl2, harvesting the cells, resuspending in chilled 50 mM CaCl 2 for about 30 minutes and adding plaanid DNA in suspension and maintaining the mixture at 0°C for about 45 minutes; the cells are resuspended in growth median for about one hour at 37 °C. Transformed host cells are selected or screened on appropriate medium.
  • the ⁇ 1059 Sau3A E. coli genomic DNA clone bank was constructed by ligating Sau3A partial digests of E. coli genomic DNA to BamHI-cleaved ⁇ 1059 arms, thus generating a bank of recombinant phage containing randan pieces of the entire E. coli genome.
  • the general methods for generating such a ⁇ 1059 Sau3A E. coli genomic DNA clone bank are well known to those skilled in the art. Clone banks using other vectors and restriction endonuclease digests are also known.
  • Plaanids are generally isolated from host cells by the Birnboim cesium chloride gradient method. (Birnboim, H.C., Doly, J., Nucleic Acids Research, 7:1513-1523 (1979).) After restriction endonuclease digestion, plaanid fractions are generally fractionated by electrophoresis on an agarose or acrylamide gel, with appropriate molecular weight standards, using a buffer of 4 mM Tris, 1 mM EDTA adjusted to pH 8.2. Fragments are subsequently washed in ethanol and resuspended in Tris EDTA buffer at pH 8.0.
  • T 4 ligase Ligation of restriction endonuclease-cut DNA fragments is generally carried out with T 4 ligase in 50 mM Tris-HCl (pH 7.8), 10 mM MgCl 2 , 20 mM dithiothreitol, 1 mM ATP and 50 ug/ml bovine serum albunin.
  • T 4 ligase may be used to catalyze the formation of phosphcdiester bonds between juxtaposed 5' phosphate and 3'-hydroxyl termini in double-stranded DNA. Both blunt and cohesive end restriction fragments may be ligated using T 4 ligase.
  • Unpaired terminal bases of restriction endonuclease cut DNA fragments are made blunt-ended with DNA polymerase I (Poll) in the presence of deoxyribonucleotides (dNTP's).
  • DNA polymerase I Polymerase I
  • dNTP's deoxyribonucleotides
  • approximately 1 micro ⁇ gram (ug) of the purified DNA fragment having unpaired terminal bases is incubated with 2 units of Klenow DNA Polymerase I (Jacobsen et al., Eur. J.
  • Media for antibiotic selection or screening of plasmid containing microorganians is formulated to sustain growth of the microorganian of interest theredn, but contains, unless otherwise indicated, 20 mg/l of the antibiotic of interest.
  • Media used in the construction of the host strains and plasmid described hereinbelow are as follows: LB per liter tryptone 10 grans (g) yeast extract 5 g sodium chloride 5 g glucose 2 g
  • Difcc ® yeast extract 5 g scdiun chloride 10 g glucose 2 g chlortetracycline 50 milligrams (mg)
  • Plates ( solid medium) are made by adding agar ( 1 .5%) .
  • Plasmid pD2643 comprising trpA-E genes of which trpA-D are under lac promoter control, lacking a trp attenuator region, carrying a tetracycline resistance gene ( tet r ) and having a ColEl-type origin of replication was constructed as follows.
  • Tandem lac promoters were removed from pKB252 ( lac PUV5) (K.
  • pCM126 was partially digested with Bglll and completely digested with SaIl restriction endonucleases.
  • a Sall-EcoRI fragment containing a gene for anthranilate synthetase resistant to feed-back inhibition by tryptophan was obtained as follows. An EcoRI digest of Serratia marcescens gencmic DNA was prepared, and fr ⁇ n an agarose gel a 4-9 kb fraction thereof was isolated. Said 4-9 kb fraction was ligated into EcoRI-digested pACYC184 under conditions favoring formation of hybrid molecules, and the resultant plaanid was used to transform E. coli strain M717 (D. Helsinki) deleted for trpE. Colonies were selected that grow on minimal medium. Plaanid pC501 carrying trpC-E was isolated from one of the selected colonies.
  • Plasmid-linked 7-methyltryptophan (7 MT) resistance was selected by treating a strain carrying pC501 with ethyl methane sulfonate and selecting for resistant mutants on minimal medium containing 7MT and tetracycline.
  • One such mutant had a plasmid gene (trpE) ceding for an anthranilate synthetase resistant to inhibition by tryptophan.
  • a 1.6 kb Sall-EcoRI fragment of the mutant derivative of pC501, having an altered trpE gene encoding an anthranilate synthetase resistant to inhibition by tryptophan was ligated into Sall-PstI digested pCM136.
  • An EcoRI-PstI fragment of pBR327 containing a tet r gene was added to this ligation mixture.
  • Plaanid pD2643 was constructed by deleting Amp r activity from pD2623 by digestion with Ahalll restriction endonuclease, ligation with the T 4 ligase, transformation of an E. coli host microorganism to Tet r and screening for ampicillin sensitivity.
  • Plasmid pD2625 Plaanid pD2625 coding for aroG activity which is feedback resistant to inhibition by aromatic amino acids (under lac control), serA and lacl activity, a par locus and a p15A origin of replication was constructed in the manner described immediately below.
  • a nucleotide sequence ( ⁇ 1059 serA) derived from an E. coli K12 genomic clone bank (Karn et al., Proc. Nat'l. Acad. Sci., 77, 9:5172-5176 (1980); clone bank obtained from M. Benedik, Stanford University) was isolated, digested with Ncol restriction endonuclease and ligated into Ncoldigested pACYC184 under conditions favoring formation of hybrid molecules.
  • E. coli serine auxotroph JC158 (A.J. Clark via B. Bachmann) was transformed to Tet r and serine independence using aliquots of the hybrid molecules.
  • pD2528 was isolated from a serine independent Tet r transformant of JC158.
  • pD2528 DNA was digested with EcoRI and SaIl and was ligated using T 4 ligase into EcoRI-Sall digested pBR327 under conditions favorable for plaanid formation.
  • pD2537 was isolated from transformants of E. coli (JC158) that were Amp r , Tet s and Ser + .
  • a bacteriophage carrying the genes of the lac operon was obtained from the ⁇ 1059-E. coli genomic bank indicated above. Lac activity was identified by complenentation of a Lac- E. coli strain (B1361) carrying plaanid pDE4081 (Mascarenhas et al. Virology, 26:658-668 (1983)) on lactose minimal plates. The ⁇ 1059 lac phage thus selected was digested with Bglll. A 10.5 kb Bglll fragment obtained from this digest was ligated to BamHI-digested pACYC184 and the hybrid was used to transform B1361 to Cam r Lac + .
  • This 1 .35 kb Narl fragment was ligated into pACYC184 digested with Clal restriction endonuclease-forming plaanid pD2333 having lacI activity, Cam r and a P15A origin from plasmid pACYC184.
  • a SaIl restriction site located between an Aval and BamHI site on plasmid pD2333 was eliminated by digestion with Aval followed by addition of Klenow Pol I, dNTP ' s, BamHI linkers and T 4 ligase. This was followed by digestion with BanHI and re-circularization of the resulting large fragment with T 4 ligase, to form pD2348.
  • Plasmid pD2348 was digested with restriction endonucleases Nrul and SaIl. The digest was combined with a 1 . 1 kb EcoRI- SaIl fragment of pEM31 containing a partition (par) locus (Meacock and Cohen, Cell , 20: 529542 (1980 ) ) , and T 4 ligase, Klenow Poll and dNTP ' s. The resulting plasmid pD2349 which is Cam r and has a P15A origin of replication, par locus and lacl activity was isolated by screening for Cam r transformants.
  • Plasmid pC520 was digested with Bglll and BanHI restriction endonucleases, and a 1.6 kb Bglll-BamHI fragment from this digest was ligated into Bglll- BamHI digested plasmid pCM126 using T4 ligase to form pD2149, a plaanid in which aroG activity is under tandem lac promoter transcriptional control.
  • pD2149 was digested with PstI to form PstI fragments. These fragments were ligated to a BamHI adaptor sequence which converts the PstI fragments ends to BamHI ends. From the converted BamHI fragments, a 2.8 kb BamHI fragment carrying the aroG gene under tandem lac promoter control was isolated by gel electrophoresis and was ligated using T 4 ligase into BanHI digested pD2349 to form pD2351 which is characterized as follows: Cam r , p15A origin, par locus, lacl activity, tandem lac promoters linked to aroG.
  • a 2-nucleotide shift in the arcG locus of pD2351 was introduced by Clal restriction endonuclease digestion in the presence of Klenow Poll and dNTP's, followed by treatment with T4 ligase.
  • the frane shift renders pD2351 incapable of expressing DAHP synthetase, the peptide product of aroG, yet conserves practically the whole arcG nucleotide sequence.
  • the plaanid with the frane shift is used to transform E. coli strain MAR13 (Held and Smith, J.
  • Gal r Tet r derivative of NK6969 (Roberts, D.) and carries a complete deletion of the aroG gene.
  • Colonies are selected for growth on minimal medium containing nicotinanide, chloramphenicol, tyrosine and tryptophan. Colonies that grow under these conditions are screened individually by enzyme assay [Doy and Brown, Bicchanica et Biophvsica. Acta., 104:377389 (1965)] to identify those which contain a feedback resistant DAHP synthetase (arcG fbr ) activity. The plaanid in one such isolate was designated pD2422.
  • Plasmid PD2434 in which the arcG fbr activity is brought under lac operator control is constructed from pD2422 as follows: a sample of plasmid pD2422 is digested with Bglll restriction endonuclease, Klenow Pol I and dNTP's to form an 8.5 kb fragment having blunt ends. The 8.5 kb ⁇ lunt-ended fragment is digested with Xhol restriction endonuclease to form a 7.4 kb fragment having one blunt end and one Xhol end.
  • Another sample of pD2422 is digested with Ddel restriction endonuclease and Klenow Pol I with dNTP's to form multiple fragments with blunt ends. These blunt ended Ddel fragments are then digested with Xhol restriction endonuclease to form a 1.0 kb fragment having an Xhol end and a blunt end. The 7.4 kb and 1.0 kb fragments are purified, mixed and ligated using T 4 ligase, to form plaanid pD2434.
  • Plasmid pD2625 was constructed from pD2434 and pD2537 in the following manner.
  • pD2537 was digested with Clal and Nrul restriction endonuclease to yield a 1.85 kb fragment having a Clal end and a blunt end.
  • a sample of pD2434 was digested with Clal and Bglll restriction endonuclease to yield a 7.7 kb fragment with a Bglll site adjacent to and downstream of the lac promoter and a Clal site in the arcGfbr gene.
  • a second sample of pD2434 was digested with XmnI and BallI restriction endonuclease to yield a 1.4 kb fragment having an XmnI end and a Bglll end.
  • the 7.7 kb fragment of pD2434, 1.85 kb fragment of pD2537 and 1.4 kb fragment of pD2434 were ligated together with T 4 ligase and were used to transform JC158 (J.C. Clark via B. Bachmann) to Cam r Ser + .
  • One of these transformants yielded plaanid pD2625.
  • a plasmid pD2624 in which the serA fragment is inserted into pD2434 in the opposite reading sense from that of pD2625 was also constructed by digesting a sample of pD2434 with Xhol and Bglll to yield a 7.4 kb fragment having Xhol and Bglll ends, and digesting a second sample of pD2434 with Xhol and Bglll as before.
  • Plasmid pD2537 was digested with SaIl and MstI to yield a 2.0 kb fragment with a Sall end and MstI blunt end. The fragments were ligated together with T4 ligase as above.
  • the SaIl end of the serA-containing fragment from pD2537 and Xhol end of the large pD2434 fragment are compatible as these two endonucleases produce compatible cohesive termini.
  • Plaanid pGM3207 (shown in Figure 2) carrying serB and serC was constructed in the manner described immediately below in Sections A-C.
  • E. coli serine auxotroph was constructed by transducing strain CGSC #5409 (argI61, argF58, serB28, purA54, thr-25, tonA49, relAl, spoT1; obtained from B. Bachmann) to PurA + with P1 phage grown on strain W3110.
  • One Pur + transductant was purified and designated G3004.
  • a nucleotide sequence ⁇ 1059 serB) derived from an E. coli K12 genomic clone bank (Karn et al., Proc. Nat' 1. Acad. Sci., 77, 9: 5172-5176 (1980); clone bank obtained from M.
  • Eenedik, Stanford University was isolated, digested with BanHI restriction endonuclease and ligated into BamHI-digested pB3339 under conditions favoring the formation of hybrid molecules.
  • E. coli serine auxotroph G3004 was then transformed to Kan r and serine independence using aliquots of the hybrid molecules.
  • Plasmid pGM3147 was isolated as a serine independent Kan r , tet s transformant of G3004.
  • Plasmid pGM3134 was digested with Bglll and Xhol restriction endonucleases, to yield a 5.3 kb Bglll-Xhol fragment containing serC.
  • a sanple of plaanid pGM3147 was digested with Bglll and Sall restriction endonucleases to yield a 9.9 kb Bglll-Sall fragment containing serB and a gene specifying kanamycin resistance.
  • the pGM3134 5.3 kb Bglll-Xhol fragment was ligated to the pGM31479.9 kb Bglll-Sall fragment with T 4 ligase.
  • the products of this ligation mixture were used to transform CGSC #4297 (serC auxotroph) to Kan r , Ser + .
  • Plaanid DNA purified from one of these transformants was used to transform G3004 (CGSC #5409 derivative and serB auxotroph, see above in Section A) to Kan r , Ser + .
  • the transforming plaanid was designated pGM3207.
  • A103 was transduced to tetracycline resistance with a P1 lysate of E. coli strain TST 1 (T.J. Silhavy via B. Bachmann).
  • TST 1 is known to carry a Tn10 insertion in the malE gene (malE52:Tn10) which is closely linked to the gene ceding for phosphoglucose isomerase (pgi).
  • Tet r colonies were selected on LB agar median with 10 mg/l tetracycline and one of these was designated A103T.
  • a nunber of spontaneously-occurring fusaric acid resistant derivatives of A103T were isolated on fusaric acid plates.
  • Fusaric acid resistant isolates were screened on glucose tetrazolion plates and those isolates which formed white colonies on this medium were tested further. One of these was found to be auxotrophic for lysine in the presence of methionine and threonine. Since the genes lysC and malE flank the pgi gene it was assumed that the lysine auxotroph had a complete deletion of the pgi locus. This isolate was designated CT10 and was assumed to be ( lysC-pgi-malE) ⁇ .
  • C534, a Tna- derivative of A103 was constructed in a manner analogous to that described above for C536.
  • Strain D2316 a strain deficient in the prcduction of phenylalanine caused by a deficiency in the pheA gene which cedes for the first enzyme of the phenylalanine biosynthetic pathway, was made by conjugation of strain C536 and strain KA197 (H. Qkestra via B. Bachmann). D2316 was selected as a Trp + phenylalanine auxotrophic transconjugant by replica plating on median either containing or lacking phenylalanine.
  • Strain D2139 was made by P1 transduction of strain MV17 (D. Helsinki, supra) with lysates of MB82 (Benedik et al. Virology, 126:658668 (1983)).
  • Strain D2316 was made Tet r by P1 transduction with lysates of strain D2139, which contains a Tn10 insertion in the trpB gene (trpB::Tn10).
  • a Tet r Trp- transductant was isolated and designated D2317.
  • D2317 was PI transduced to 3-fluorotyrosine resistance with lysates of D2307 described above.
  • D2318 characterized as tryptophan independent, 3-fluorotyrosine resistant and phenylalanine-requiring was one of the transductants obtained.
  • D2318 was P1 transduced using lysates of strain AT2471 (A.L. Taylor via B. bachmann), a tyrA mutant strain. Phenylalanine-independent colonies were selected by growth on median containing tryosine but lacking phenylalanine. Phenylalanine-independent colonies were screened for tyrosine dependence and a Phe + Tyr- strain was isolated and designated D2320.
  • a strain having feedback resistant anthranilate synthetase was constructed from strain D2320 by first making D2320 Tet r by P1 transduction with lysates of D2319.
  • the trpB::Tn10 sequence was introduced into D2320 in a manner analogous to that used in making D2317.
  • One Tet r transductant (D2324) was P1-transduced using lysates of a spontaneously occurring derivative of W3110 having anthranilate synthetase resistant to feedback inhibition by tryptoph.an.
  • a tryptophan independent, 7-methyltrypto ⁇ hanresistant transductant that was auxotrophic for tyrosine and sensitive to tetracycline was selected and designated D2325.
  • Enzyme assays (according to Ito and Crawford, Genetics, 52: 1303-1316 (1965)) in the presence of 2 mM L-tryptophan confirmed that D2325 specified a feedback-resistant anthranilate synthetase.
  • a strain designated D2327 which is auxotropic for phenylalanine and tyrosine independent was made by P1 transduction of D2325 to Tyr + using lysates of strain KA197. (Hoekstra via B. Bachmann).
  • Strain D2327 was made Tet r by P1 transduction with lysates of an E. coli strain (C541) having a Tn10 insertion in the nadA locus and an adjacent deletion removing nadA, aroG, gal. C541 was made by P1 transduction of MV17 (D. Helsinki, supra) with lysates of strain C531. The Tet r derivative of D2327 was then transduced using P1 lysates of strain MAR13 (Held and Smith, supra). Marl 3 carries an arcmatic anino acid feedback resistant DAHP synthetase activity. Transduced cells were isolated as Nad + , Phe-, tetracycline sensitive strains.
  • D2346 In one transductant, feedback resistance of DAHP synthetase to phenylalanine was determined by enzyme assay in the presence of 1 mM phenylalanine. This strain was designated D2346.
  • a phenylalanine independent strain of D2346 was made by P1 transduction of D2346 using lysates of AT2471 (A.L. Taylor, supra) and selecting for phenylalanine independence on median containing tyrosine.
  • One Phe + Tyr- transductant was designated D2402.
  • B1364 is a trp + lac + transductant of B1363 (Mascarenhas et al., Virology, 124:100-108, (1983)) using P1 lysates of W3110.
  • B1364 thus has genetic information for ⁇ -galactosidase, lactose transacetylase, and lactose permease activity all fused to and under the control of the tryptophan operon ( ⁇ trp-lac W205).
  • Strain D2402 was made Tet r by P1 transduction using a lysate of D2139 as above; a Tet r derivative of D2402 was then transduced to Trp + ac + with P1 lysates of strain B1364.
  • Trp + Lac + Tet s 7-methyl-tryptophan resistant (7MT r ) isolate was designated D2432.
  • D2432 was made Tet r by P1 transduction using P1 lysates of strain RS162 (J. Wechsler via B. Bachnann) .
  • the resulting Tet r strain (D2548) has a Tn10 insertion in the zjb locus and a temperature sensitive mutation dnaB252.
  • a spontaneous isolate of this strain capable of utilizing hydroxyphenyl pyruvate was isolated and designated D2549.
  • D2549 was P1-transduced using lysates of strain EG30 (D, Gelfand via B. Bachmann), a strain lacking transaninase A (tyrB-).
  • Transductants were isolated by growth on LB agar at 42°C (loss of dnaB252 mutation) and screened for inability to grow on plates containing p-hydroxyphenylpyruvate.
  • One such isolate was designated D2550.
  • a spontaneous tetracycline sensitive (fusaric acid resistant) derivative of D2550 designated D2618 was selected on fusaric acid plates. D2618 was then made Tet r by P1 transduction using lysates of NK6024 (N. Kleckner via B. Bachmann), a strain having a Tn10 insertion in the pheA locus. Tetracycline resistant colonies were selected and one Phe-Tyr- transductant was designated D2636. Spontaneous fusaric acid resistant (Tet s ) derivatives of D2636 were selected on fusaric acid plates and checked for phenylalanine and tyrosine requirements. One such isolate (Phe-Tyr-Tet s ) was designated D2637.
  • D2637 was transduced to Tet r (Ser-) using P1 lysates of strain 123A1, which contain a Tn10 insertion linked to the serC locus in strain strain KL282 (K. B. Low via B. Bachmann).
  • One Tet r Ser- transductant, designated D2638 was transduced to Ser + with P1 lysates from DG30 (D. Gelfand via B. Bachmann) which contains an aspC mutation and is auxotrophic for aspartic acid. These transductants were screened for aspartic acid auxotrophy.
  • One aspartic acid auxotroph that was serine independent and Tet S was designated D2639.
  • Serine deaninase-deficient derivatives of D2637 were constructed as follows: Strain MEW191 and a P1-sensitive derivative of strain 1K15-5 (both strains received from E. Newman, Concordia University) are believed to carry mudX ( Cam,Amp) insertions in regulatory and structural genes for L-serine deaminase, respectively. A P1 lysate of each of these strains was used to transduce D2637 to Cam r Mp r . Single transductants from each cross were designated D2711 and D2713 respectively, and were deemed to carry the mudX (Cam, Mp) insertions (regulatory:D2711, structural:D2713) present in their respective parents.
  • mudX Cam,Amp
  • D2714 and D2715 were isolated and designated D2714 and D2715 respectively. Enzyme assays confirmed that both D2714 and D2715 were deficient in L-serine deaminase activity.
  • C534 and C536 are isogenic E. coli strains except that the pgi gene has been deleted in C536.
  • C534 was made by PI transduction of A103 using lysates grown on C537 and screening for Tna- colonies.
  • C536 was described above. These strains were cured of their resident plasmids by isolation of Amp s segregants in each case. These cured derivatives were then transduced to Tet R with P 1 grown on D2636 (tyrA4 pheA18: :Tn10 ) .
  • D2704 Single transductants were then cured of the transposon by selection of spontaneous fusaric-acid-resistant segregants on fusaric acid plates.
  • D2704 was Pgi + Tyr-Phe-Tet s (derived from C534 ) .
  • D2704 and D2705 were each transformed sequentially with pD2634, pD2643 and pD2625 - by selection for Amp R , Tet R and Cam R , respectively, using conventional calcium shock to render the host competent for transformation.
  • These plasmids carry the genes for the key enzymes of tryptophan biosynthesis and were described hereinafccve.
  • One triple transformant in each case was used for nuclear magnetic resonance (NMR) analysis.
  • This culture was transferred to an NMR tube and used directly for N MR spectroscopy at 28 °C using a Varion Associates XL200 NMR spectrcmetry system. Aeration of the culture was achieved by rotating the tube and pumping air through the culture during the run. Spectra were acquired at 3-hour intervvls. Analysis of results
  • Table II summarizes the efficiency of conversion of glucose to tryptophan by the strains described immediately above.
  • Fran the intensity of the peaks of the NMR spectra corresponding to C6-glucose and C6-tryptophan, one can calculate the increase in tryptophan relative to the decrease in glucose (after making allowance for the molecular weights of the two compounds).
  • strains also carry the following markers: (argF-lac) U169, arcG FBR , ⁇ (trp-lac) W205, trpE fbr 31, tyrR366, tyrA4, tna2, bglR6, (lysC-pgi-malE) , trpR, (anthranilate-resistance).
  • the genotype of the host strain, D2618 is as follows: W3110 F-( argF-lac) U169, aroG PBR , ⁇ (trp-lac) W205, trpE FBR 31, tyrR366, tyrA4, tna2, bglR6, (lysC-pgi-malE) , tyrB507, zjb, trpR, (anthranilate-resistance).
  • D2715 is derived from D2618 by introducing deletions into the pheA gene and into the structural gene for serine deaminase.
  • the general method according to the invention comprises the steps of transforming an E . coli host deficient in tryptophanase with plasmid-borne genetic information to control tryptophan prcduction divided between at least two plaanids, growing the transformed host in an appropriate nutrient median for a period of time sufficient to produce tryptophan as exemplified above, and producing tryptophan by the transformed host.
  • Tryptophan from the culture broth may be removed by any conventional technique.
  • the tryptophan so obtained may be further refined or purified as desired.
  • the host in addition to being Tna-, will be deficient in the activity of phosphoglucose isomerase (pgi-).
  • the host in addition to or instead of being pgi-, may also have DAHP synthetase activity resistant to aromatic anirio acid inhibition, anthranilate synthetase activity resistant to tryptophan innibition, deficiencies in the activity of lac repressor, aromatic transaminase A, L-serine deaninase either singly or in any combinations thereof.
  • the inventor has also provided a method for increasing the production of tryptophan in a host of the genus Escherichia, particularly E. coli by transforming an E.coli host deficient in the enzyme tryptophanase with a plaanid carrying plaanid-borne genetic information to control tryptophan production, a portion of said information including lac operator/promoter control, growing the transformed host in an appropriate median as exemplified above and prcducing tryptophan by the transformed host.
  • the E. coli host will have the additional characteristics described above with respect to pgi-, DAHP synthetase, anthranilate synthesis, lac repressor activity, aromatic transaminase and L-serine deaminase.
  • the preferred E. coli host is transformed with plasmid-borne genetic information to control tryptophan production divided between at least two plaanids, a portion of the information to control tryptophan prcduction being under lac operator/promoter control.

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Microorganismes d'Escherichia coli véhiculant des informations génétiques portées par les plasmides et relatives à la production de L-tryptophane, et procédés permettant de produire ou d'accroître la production de L-tryptophane par fermentation.Escherichia coli microorganisms carrying genetic information carried by the plasmids and relating to the production of L-tryptophan, and methods for producing or increasing the production of L-tryptophan by fermentation.

Description

TRYPTOPHAN PRODUCING MICROORGANISM
Cross reference to Related Applications This application is a continuation-in-part of application Serial No. 642,303, filed August 20, 1984.
Background of the Invention The present invention relates to Escherichia coli (E. coli) microorganisns carrying plasmid borne genetic information for the prcduction of L-tryptophan and methods for prcducing and increasing the fermentative production of L-tryptophan.
Brief Description of Relevant Art Tryptophan is an amino acid that is an essential component in animal nutrition. Its fermentative production by microorganisns from inexpensive carbohydrate substrates is highly desirable.
Fermentative production of tryptophan, using microorganism strains artificially mutated and selected for increased tryptophan production is known. Microorganisms used to this end include Brevibacterium (U.S. Pat. 3,700,539), Enterobacter (U.S. Pat. 4,439,627), Bacillus, particularly Bacillus subtilis [using anthranilate and carbon, nitrogen and mineral sources (U.S. Pat. 4,363,875; Japanese Patent Application J58017190, 1,3-5A, and European Patent Application EP 81-107)] and Corynebacterium glutamicum ATCC 21851.
The application of recombinant DNA methods for the construction of E. coli strains for tryptophan production, has been described in a limited way in U.S. Pat. 4,371,614. The E. coli strains described therein carry a specific plasmid having thereon genes of the wild type tryptophan operon ( trpA-E ) with a wild type or temperature sensitive tryptophan repressor gene (trpR or trpRts, respectively) for control of tryptophan biosynthesis. Such plasmid or multicopy plasmid according to U.S. Patent 4,371,614 may also carry a Serine B gene (SerB). This is particularly desirable when the host strain is a tryptophan or L-serine auxotroph (i.e., Trp-, Ser-). Maximum yields disclosed are about 230 ppm of tryptophan. This same patent also decribes a number of general methods known to those skilled in the art for carrying out alterations to chromosomal DNA and plaanid DNA, the transformation of microorganism with plasmid DNA, and the selection of microorganian so altered or transformed. U.S. Patent 4,371,614 is hereby incorporated by reference for the purpose of illustrating the general state of the known methods in the field to which the present invention pertains.
A need for inexpensively produced tryptophan and methods for the prcduction of tryptophan as well as methods for increasing yields of tryptophan produced by microorganisms persists.
Objects of the Invention The present invention is intended to meet the persistent need for inexpensively produced tryptophan by providing a bacterial host microorganism, of the genus Escherichia, deficient in the enzyme tryptophanase carrying plaanid borne information for the production of tryptophan wherein said information is divided between at least two plaanids.
Another object of the invention is to provide a method for producing tryptophan by culturing the above-mentioned bacterial host and plaanids therein in a culture medium and recovering L-tryptophan from the fermented culture medium.
Still another object of the invention is to provide inexpensively produced tryptophan by providing a bacterial host microorganian of the genus Escherichia deficient in the enzyme tryptophanase carrying plaanid borne genetic information for the prcduction of tryptophan wherein a portion of said information for the production of tryptophan is under lac operator/promoter control.
Yet another object of the invention is to provide a method for producing tryptophan by culturing the above-mentioned bacterial host with plaanid borne information for the prcduction of tryptophan, a portion of said information being under lac operator/promoter control in a culture medium and recovering tryptophan from the fermented culture median. A still further object of the invention is to increase the production of tryptophan by a bacterial host of the genus Escherichia deficient in the enzyme tryptophanase by transforming said host with plasmid borne information to control tryptophan production divided between at least two plaanids; or by transforming the bacterial host as described with plaanid borne information to control tryptophan production a portion of said information being under lac promoter/operator control, or by transforming said host as described with plasmid borne information to control tryptophan prcduction divided between at least two plaanids, a portion of said information to control tryptophan prcduction being under lac operator/promoter control.
Summary of the Invention The plaanids used in this invention may be E. coli plaanids or plaanids capable of replicating in E. coli. If the information to control tryptophan prcduction is distributed on more than one plasmid, it is desirable to use plaanids that are replication compatible. Thus, for example, when the information to control tryptophan prcduction is distributed on two plaanids, plaanids having a ColE1 origin of replication may be used to carry part of the information and plaanids having a p15A origin of replication may be used to carry another part of the information.
Useful in the plasmid constructions of the type described in the invention are the following: ColEl, pSC101, pSF2124, pMB3, pMB9, pACYC184, pACYC177, pCK1, R6X, pBR312, pBR313, pBR317, OBR318, pBR320, PSR321, pBR322, pBR333, pBR341, pBR345, pBR350, pBR351, pML2, pML21, ColElaD, RSF1010, pVH51, pVh151, pVH153 (Recombinant Molecules: Impact on Science and Society: Beers, R.F., and Bassett, E.G., eds. Raven Press, New York (1977)). Other plaanids are pBR327, pBR325 and pBR328 (Soberon, et al., Gene, 9:287-305 (1980). Plasmid p15A is described in Cha ng A.C.Y and Cohen, S., J. Bacteriol., 135: 1148-1156 (1978). pHH509 is described in Barth et al., J. Bacteriol., 135:760-765 (1978), and pLG339 is described in Stoker et al., Gene 18:335-341 (1982). Still others are described in "DMA Insertion Elenents, Plaanids and Episomes," Bukhari et al. (eds.) Cold Spring Harbor Laboratory (1977). The preferred plasmids are the multicopy plaanids of the type of pBR and its derivatives, ColEl and its derivatives, p15A and its derivatives, pHH509 and its derivatives and pSC101 and its derivatives.
To ensure equal distribution of the plaanids in daughter cells during growth of the microorganism, it may furthermore be desirable for at least one of the plaanids to contain a par locus (Meacock, P.A. and Cohen, S.N., Cell, 20:529-542 (1980)). If the information to control tryptophan production is distributed anong more than two plaanids it is preferred that all plaanids be replication compatible with each other, by constructing them such that they each carry different origins of replication.
The plaanids used in the invention are single copy (stringent) or multicopy (relaxed) plasmids. Because tryptophan yields can be increased by increasing the copy nunber of plaanids carrying information multicopy plaanids are preferred. Although multicopy plaanids can be frequently lost from the host cell, i.e., are unstable, plasmid copy nunber may be maintained by constructing the plasmids such that determinants of antibiotic resistance are carried thereon. By adding antibiotics to the culture medium, microorganisms that lose plasmids are eliminated or fall to insignificant nunbers, depending on the mode of antibiotic action.
Plasmids used in this invention bear genetic information to control tryptophan production. The term "information to control tryptophan production" according to the invention includes:
1. information controlling the biosynthesis of the common precursors of the aromatic anino acids: tryptophan, tyrosine and phenylalanine; 2. information for the biosynthesis of tryptophan from chorianic acid via several intermediate steps;
3. information controlling the oiosynthesis of serine which is required in the final step of the tryptophan biosynthetic pathway; and 4. controlling elements for the information of 1 and 2.
The controlling elements used in the invention are nucleotide sequences derived from the lactose operon and include the lac operon promoter/ operator and lac repressor sequences. According to the invention, various portions of 1 and 2 are under lac control and produce significant amounts of functional gene products only in the presence of lactose. According to the invention it is preferred that tandem lac operator/promoters are used to achieve greater levels of gene expression than are possible with a single lac promoter.
The genetic information to control tryptophan prcduction according to the invention comprises a large nαnber of DNA sequences ceding for genes and regulatory sequences thereof, which are plaanid borne. The terms "gene" or "genes" as used herein are meant to encompass a DNA sequence ceding for an active product of the gene. Thus, DNA sequences ceding for an active gene product are genes within this definition even though the particular DNA sequence may not include the complete structural gene for the active product of the gene.
In placing this genetic information to control tryptophan production on plaanids it is convenient to divide the genetic information between at least two plasmids. By dividing the genetic information to control tryptophan prcduction between at least two plasmids, the elenents can be positioned relative to information they control and their gene products can be produced in sufficient concentration to insure that the information controlling biosynthesis of the common aromatic amino acid precursors, information controlling biosynthesis of tryptophan from chorismic acid and/or information controlling biosynthesis of serine are expressed under optimum conditions and at the desired time in a fermentation cycle. Thus, in a preferred embodiment the plaanid-borne information to control tryptophan prcduction is divided between at least two plasmids.
Brief Description of the Drawing The invention and its advantages over the known prior art can be best appreciated by those skilled in the art from the following detailed description of the invention considered along with the accompanying drawings.
Figure 1 and Figure 2 are schematic drawings of the preferred embediments of the plaanids carrying information to control tryptophan production according to the invention. Fragment Numbers 1-11 of Table 1 read in conjunction with Figure 1 identifying each restriction endonuclease segment of each plaanid. Similarly, Fragment Numbers 12-14 identify the restriction endonuclease segments of the plaanid within Figure 2. Table 1 further identifies each segment by approximate size in kilobases (kb), restriction nuclease ends of each fragment, genes/loci on the fragment, sequence coordinates if known, and journal reference for each known sequence coordinate. The depicted segment sizes in Figure 1 are only approximately proportional to the size of the complete plaanid as shown.
In the drawings, table and in the detailed description of the invention which follows the abbreviations indicated below are used and denote restriction endonuclease enzymes from the following organisms:
Restriction Endonculease Source organism
EcoRI Escherichia coli RY13
Eglll Bacillus globigii
SaIl Streptcmyces albis G
PstI Providencia stuartii 164
Sau3Al Staphylococcus aureus 3A(1)
SphI Streptcmyces phaechrcmogenes
Narl Nocardia argentinensis
Clal Caryophanon 1aturn
Aval Anabaena variabilis
BamHI Bacillus amyloliguifaciens H
Xhol Xanthcmonas holicola
Ddel Desulfovibrio desulfuricans
Nrul Nocardia rubra
Xmnl Xanthomonas manihotis
MstI Microcoleus sp.
Ncol Nocardia coralina
Hindlll Haemophilus influenzae Rd
Ahalll Apanatheca holophytica
SstI Streptomyces Stanford
Experimental Methods In the construction of the host strains and plasmids according to the invention, a number of methods known to those skilled in the art are employed. These methods are substantially described in numerous journals and those cited herein are well known examples of such method descriptions.
Transduction using P1 phage lysates is described in Rosner, J.L., Virology, 49:679-689 (1972). The use of Tn10 transposable elements for insertion into and deletion of chromosomal regions is described in Kleckner, N. et al., Proc. Nat. Acad. Sci., USA 73:3838-3842 (1976). Transformation of host strains with the plaanids according to the invention is carried out by calcium shock of the host strain rendering the host capable of incorporating DNA as described, for example, in Morrison, D.A. et al., J. Bacteriol., 132:342-351 (1977). Alternatively, E. coli host strains may be transformed by growing them to an optical density of about 0.6 at 600 nanometers in liquid median, chilling the cell suspension on ice for approximately 5 minutes, harvesting the cells by centrifugation, washing the cells in chilled 10 mM MgCl2, harvesting the cells, resuspending in chilled 50 mM CaCl2 for about 30 minutes and adding plaanid DNA in suspension and maintaining the mixture at 0°C for about 45 minutes; the cells are resuspended in growth median for about one hour at 37 °C. Transformed host cells are selected or screened on appropriate medium.
The λ 1059 Sau3A E. coli genomic DNA clone bank was constructed by ligating Sau3A partial digests of E. coli genomic DNA to BamHI-cleaved λ1059 arms, thus generating a bank of recombinant phage containing randan pieces of the entire E. coli genome. (Karn et al., Proc. Nat'l. Acad. Sci., USA vol. 77 9:5172-5176 (1980).) The general methods for generating such a λ 1059 Sau3A E. coli genomic DNA clone bank are well known to those skilled in the art. Clone banks using other vectors and restriction endonuclease digests are also known.
Plaanids are generally isolated from host cells by the Birnboim cesium chloride gradient method. (Birnboim, H.C., Doly, J., Nucleic Acids Research, 7:1513-1523 (1979).) After restriction endonuclease digestion, plaanid fractions are generally fractionated by electrophoresis on an agarose or acrylamide gel, with appropriate molecular weight standards, using a buffer of 4 mM Tris, 1 mM EDTA adjusted to pH 8.2. Fragments are subsequently washed in ethanol and resuspended in Tris EDTA buffer at pH 8.0.
Ligation of restriction endonuclease-cut DNA fragments is generally carried out with T4 ligase in 50 mM Tris-HCl (pH 7.8), 10 mM MgCl2, 20 mM dithiothreitol, 1 mM ATP and 50 ug/ml bovine serum albunin. T4 ligase may be used to catalyze the formation of phosphcdiester bonds between juxtaposed 5' phosphate and 3'-hydroxyl termini in double-stranded DNA. Both blunt and cohesive end restriction fragments may be ligated using T4 ligase.
Unpaired terminal bases of restriction endonuclease cut DNA fragments are made blunt-ended with DNA polymerase I (Poll) in the presence of deoxyribonucleotides (dNTP's). In general, approximately 1 micro¬gram (ug) of the purified DNA fragment having unpaired terminal bases is incubated with 2 units of Klenow DNA Polymerase I (Jacobsen et al., Eur. J. Biochem., 45:623-627 (1974)), 10 mM β-mercaptoethanol, 6 mM Tris-HCl (pH 7.5), 8 mM magnesiαn chloride and 0.2 mM each of the following dNTP's: deoxyadenosine triphosphate (dA-CP), deoxycytidine triphosphate (dCTP), thymidine triphosphate (TTP) and deoxyguanosine triphosphate (dGTP). The reaction is run at 16ºC for 60 minutes and is terminated by heat inactivation at 65ºC for 10 minutes followed by rapid cooling on ice.
A number of strains used in making the host strain according to the invention were obtained from the E .coli Genetic Stock Center (CGSC) Department of Human Genetics, Yale University School of Medicine, P.O. Box 3333, Cedar Street, New Haven, Connecticut 06510, USA. Strains obtained from the CGSC are designated herein by a researcher's name "via B. Bachnann", curator for CGSC.
Media for antibiotic selection or screening of plasmid containing microorganians is formulated to sustain growth of the microorganian of interest theredn, but contains, unless otherwise indicated, 20 mg/l of the antibiotic of interest. Media used in the construction of the host strains and plasmid described hereinbelow are as follows: LB per liter tryptone 10 grans (g) yeast extract 5 g sodium chloride 5 g glucose 2 g
LB plates = LB + 1.5% agar LB Mg = LB + 0.01M MgCI2 LB Ca = LB + 0.005M CaCl2 LB Top Agar = LB + 0.75% agar Saline = 0.85% NaCl
Fusaric Acid Plates agar 15 g
Difcc® tryptone 10 g
Difcc® yeast extract 5 g scdiun chloride 10 g glucose 2 g chlortetracycline 50 milligrams (mg)
NaH2PO4H2O 10 g
autoclave, cool, then add 6 ml 2 mg/ml fusaric acid 5 ml zinc chloride 20 mM
Minimal Media per liter citric acid 2 g 80% H3PO44.9 g KC14 g
30% NH3 solution 5.86 g FeSO4.7H2O 1 mg MnSO4 1 mg MgSO4.7H2O 1 g thiamine-HCl 3.5 mg Supplements to Minimal Plates amino acids 20 micrcmoles/milliliter (ug/ml) tetracycline 10 ug/ml
-2-thienyl-DL-alanine 20 ug/ml Difcc® casamino acids 0.4% 3-fluoro tryptophan (20 ug/ml) 7-methyl tryptophan (20 ug/ml) biotin 1 ug/ml thiamine 1 ug/ml triphenyltetrazolium chloride (20 ug/ml)
Vogel-Bonner Minimal Medium (per liter)
MgSO4.7H2O 0.2 g citric acid 2 g K2H PO4 10 g NaNH4PO4.4H2O 3.5 g
Make 0.4% glucose after autoclaving. Plates ( solid medium) are made by adding agar ( 1 .5%) .
CONSTRUCTION OF SPECIFIC PLASMIDS Construction of Plaanid pD2643 Plasmid pD2643 comprising trpA-E genes of which trpA-D are under lac promoter control, lacking a trp attenuator region, carrying a tetracycline resistance gene ( tetr) and having a ColEl-type origin of replication was constructed as follows.
Tandem lac promoters were removed from pKB252 ( lac PUV5) (K.
Backman et al. , Proc. Nat' 1. Acad. Sci. USA, 73: 4124-4178 (1976 ) ) by partial digestion with EcoRI and complete digestion with SaIl restriction endonucleases under buffer conditions suggested by the manufacturer, and were ligated using T4 ligase into plasmid pBR327 which had been previously digested to completion by SaIl and EcoRI. After trans forming E. coli , tetracycline resistant (Tetr) ampicillin resistant (Ampr) colonies were isolated. The resident plaanid in one of these was designated pEMl 26.
pCM126 was partially digested with Bglll and completely digested with SaIl restriction endonucleases. A 5.8 kilobase ( kb) Bglll-Sall fragment derived from pCB107 (Mascarenhas et al. , Virology, 24: 100-108 (1 983 ) ) carrying the trpD, C, B, A genes and lacking most of trpE gene as well as the attenuator and promoter regions of the trp operon (corresponding to nucleotides 1190-7015 identified by Yanofsky et al., Nucl. Acids Fes., 9:6647-6668 (1981)) was ligated using T4 ligase into the Bglll, Salldigested pCM126 forming a mixture of ligated DNA. Plaanid pEMl36, having trpA-D under lac control was identified by transforming strain AE2
(Eenedik et al., Virology, 126:653-668 (1983)), which lacks trpA-E, with the ligated DNA and selecting transformed microorganisms on minimal medium containing ampicillin and anthranilate.
A Sall-EcoRI fragment containing a gene for anthranilate synthetase resistant to feed-back inhibition by tryptophan was obtained as follows. An EcoRI digest of Serratia marcescens gencmic DNA was prepared, and frαn an agarose gel a 4-9 kb fraction thereof was isolated. Said 4-9 kb fraction was ligated into EcoRI-digested pACYC184 under conditions favoring formation of hybrid molecules, and the resultant plaanid was used to transform E. coli strain M717 (D. Helsinki) deleted for trpE. Colonies were selected that grow on minimal medium. Plaanid pC501 carrying trpC-E was isolated from one of the selected colonies.
Plasmid-linked 7-methyltryptophan (7 MT) resistance was selected by treating a strain carrying pC501 with ethyl methane sulfonate and selecting for resistant mutants on minimal medium containing 7MT and tetracycline. One such mutant had a plasmid gene (trpE) ceding for an anthranilate synthetase resistant to inhibition by tryptophan.
A 1.6 kb Sall-EcoRI fragment of the mutant derivative of pC501, having an altered trpE gene encoding an anthranilate synthetase resistant to inhibition by tryptophan was ligated into Sall-PstI digested pCM136. An EcoRI-PstI fragment of pBR327 containing a tetr gene was added to this ligation mixture. Plasmid pD2623 ceding for "the activities of the trpA-D genes under lac control and for trpE (feedback resistant anthranilate synthetase) and which specifies Tetr and Ampr was identified by transforming strain MV17 which is a tryptophan auxotroph, selecting for Tetr-Ampr and screening these colonies for growth in the absence of tryptophan (i.e., tryptophan independence) on minimal mediun. Plaanid pD2643 was constructed by deleting Ampr activity from pD2623 by digestion with Ahalll restriction endonuclease, ligation with the T4 ligase, transformation of an E. coli host microorganism to Tetr and screening for ampicillin sensitivity.
Construction of Plasmid pD2625 Plaanid pD2625 coding for aroG activity which is feedback resistant to inhibition by aromatic amino acids (under lac control), serA and lacl activity, a par locus and a p15A origin of replication was constructed in the manner described immediately below.
A. Construction of serA-Containing Donor Plaanids
A nucleotide sequence ( λ1059 serA) derived from an E. coli K12 genomic clone bank (Karn et al., Proc. Nat'l. Acad. Sci., 77, 9:5172-5176 (1980); clone bank obtained from M. Benedik, Stanford University) was isolated, digested with Ncol restriction endonuclease and ligated into Ncoldigested pACYC184 under conditions favoring formation of hybrid molecules. E. coli serine auxotroph JC158 (A.J. Clark via B. Bachmann) was transformed to Tetr and serine independence using aliquots of the hybrid molecules. pD2528 was isolated from a serine independent Tetr transformant of JC158. pD2528 DNA was digested with EcoRI and SaIl and was ligated using T4 ligase into EcoRI-Sall digested pBR327 under conditions favorable for plaanid formation. pD2537 was isolated from transformants of E. coli (JC158) that were Ampr, Tets and Ser+.
B. Construction of lad Activitv Donor Plasmids
A bacteriophage carrying the genes of the lac operon was obtained from the λ1059-E. coli genomic bank indicated above. Lac activity was identified by complenentation of a Lac- E. coli strain (B1361) carrying plaanid pDE4081 (Mascarenhas et al. Virology, 26:658-668 (1983)) on lactose minimal plates. The λ 1059 lac phage thus selected was digested with Bglll. A 10.5 kb Bglll fragment obtained from this digest was ligated to BamHI-digested pACYC184 and the hybrid was used to transform B1361 to Camr Lac+. A 4.2 kb Eco Rl-SphI sub-fragment of this plaanid was then ligated to a 2.7 kb Eco Rl-SphI fragment previously obtained frcm pBR327, to form pD2329. Finally, digestion of ρD2329 with Narl restriction endonuclease yielded a 1.85 kb Narl fragment with lacI sequences frcm about 100 base pairs upstrean of the lacl promoter to base pair nunber 1020 in the lacI DNA sequence reported by Farabaugh in Nature, 274: 765-769 ( 1978) . This 1 .35 kb Narl fragment was ligated into pACYC184 digested with Clal restriction endonuclease-forming plaanid pD2333 having lacI activity, Camr and a P15A origin from plasmid pACYC184. A SaIl restriction site located between an Aval and BamHI site on plasmid pD2333 was eliminated by digestion with Aval followed by addition of Klenow Pol I, dNTP ' s, BamHI linkers and T4 ligase. This was followed by digestion with BanHI and re-circularization of the resulting large fragment with T4 ligase, to form pD2348.
Plasmid pD2348 was digested with restriction endonucleases Nrul and SaIl. The digest was combined with a 1 . 1 kb EcoRI- SaIl fragment of pEM31 containing a partition (par) locus (Meacock and Cohen, Cell , 20: 529542 (1980 ) ) , and T4 ligase, Klenow Poll and dNTP ' s. The resulting plasmid pD2349 which is Camr and has a P15A origin of replication, par locus and lacl activity was isolated by screening for Camr transformants.
C. Construction of aroGfbr Donor Plasmid A bacteriophage carrying the arcG gene of E. coli was selected from the λ 1059-E. coli genomic bank indicated above by complementation of an Aro- (arcG) strain, C531 , described below, carrying plaanid pDE4081. A 5.8 kb BamHI- SaIl fragment of DNA from this bacteriophage was subcloned into BamHI-Sall digested pACYC184 to form pC520.
Construction of pD2625 From Donor Plasmids Plasmid pC520 was digested with Bglll and BanHI restriction endonucleases, and a 1.6 kb Bglll-BamHI fragment from this digest was ligated into Bglll- BamHI digested plasmid pCM126 using T4 ligase to form pD2149, a plaanid in which aroG activity is under tandem lac promoter transcriptional control.
pD2149 was digested with PstI to form PstI fragments. These fragments were ligated to a BamHI adaptor sequence which converts the PstI fragments ends to BamHI ends. From the converted BamHI fragments, a 2.8 kb BamHI fragment carrying the aroG gene under tandem lac promoter control was isolated by gel electrophoresis and was ligated using T4 ligase into BanHI digested pD2349 to form pD2351 which is characterized as follows: Camr, p15A origin, par locus, lacl activity, tandem lac promoters linked to aroG.
A 2-nucleotide shift in the arcG locus of pD2351 was introduced by Clal restriction endonuclease digestion in the presence of Klenow Poll and dNTP's, followed by treatment with T4 ligase. The frane shift renders pD2351 incapable of expressing DAHP synthetase, the peptide product of aroG, yet conserves practically the whole arcG nucleotide sequence. The plaanid with the frane shift is used to transform E. coli strain MAR13 (Held and Smith, J. Bacteriol., 101:202-208 (1970)), a strain carrying chromosomal aroG activity which is feedback resistant to inhibition by phenylalanine and hence resistant to aromatic anino acid inhibition. In this transformant, low frequency homologous exchange of DNA between the Mar13 chromosomal arcG and the plaanid pD2351 (frane- shifted) aroG gene occurs. Plasmid DNA is isolated from this strain by conventional methods and is used to transform E. coli strain C531 which is a spontaneous
GalrTetr derivative of NK6969 (Roberts, D.) and carries a complete deletion of the aroG gene. Colonies are selected for growth on minimal medium containing nicotinanide, chloramphenicol, tyrosine and tryptophan. Colonies that grow under these conditions are screened individually by enzyme assay [Doy and Brown, Bicchanica et Biophvsica. Acta., 104:377389 (1965)] to identify those which contain a feedback resistant DAHP synthetase (arcGfbr) activity. The plaanid in one such isolate was designated pD2422.
Plasmid PD2434 in which the arcGfbr activity is brought under lac operator control is constructed from pD2422 as follows: a sample of plasmid pD2422 is digested with Bglll restriction endonuclease, Klenow Pol I and dNTP's to form an 8.5 kb fragment having blunt ends. The 8.5 kb υlunt-ended fragment is digested with Xhol restriction endonuclease to form a 7.4 kb fragment having one blunt end and one Xhol end.
Another sample of pD2422 is digested with Ddel restriction endonuclease and Klenow Pol I with dNTP's to form multiple fragments with blunt ends. These blunt ended Ddel fragments are then digested with Xhol restriction endonuclease to form a 1.0 kb fragment having an Xhol end and a blunt end. The 7.4 kb and 1.0 kb fragments are purified, mixed and ligated using T4 ligase, to form plaanid pD2434.
Plasmid pD2625 was constructed from pD2434 and pD2537 in the following manner. pD2537 was digested with Clal and Nrul restriction endonuclease to yield a 1.85 kb fragment having a Clal end and a blunt end. A sample of pD2434 was digested with Clal and Bglll restriction endonuclease to yield a 7.7 kb fragment with a Bglll site adjacent to and downstream of the lac promoter and a Clal site in the arcGfbr gene.
A second sample of pD2434 was digested with XmnI and BallI restriction endonuclease to yield a 1.4 kb fragment having an XmnI end and a Bglll end. The 7.7 kb fragment of pD2434, 1.85 kb fragment of pD2537 and 1.4 kb fragment of pD2434 were ligated together with T4 ligase and were used to transform JC158 (J.C. Clark via B. Bachmann) to CamrSer+. One of these transformants yielded plaanid pD2625.
A plasmid pD2624 in which the serA fragment is inserted into pD2434 in the opposite reading sense from that of pD2625 was also constructed by digesting a sample of pD2434 with Xhol and Bglll to yield a 7.4 kb fragment having Xhol and Bglll ends, and digesting a second sample of pD2434 with Xhol and Bglll as before. Plasmid pD2537 was digested with SaIl and MstI to yield a 2.0 kb fragment with a Sall end and MstI blunt end. The fragments were ligated together with T4 ligase as above. The SaIl end of the serA-containing fragment from pD2537 and Xhol end of the large pD2434 fragment are compatible as these two endonucleases produce compatible cohesive termini.
Construction of Plaanid pGM3207 Plaanid pGM3207 (shown in Figure 2) carrying serB and serC was constructed in the manner described immediately below in Sections A-C.
A. Construction of serB-Containing Donor Plaanid
An E. coli serine auxotroph was constructed by transducing strain CGSC #5409 (argI61, argF58, serB28, purA54, thr-25, tonA49, relAl, spoT1; obtained from B. Bachmann) to PurA+ with P1 phage grown on strain W3110. One Pur+ transductant was purified and designated G3004. A nucleotide sequence ( λ 1059 serB) derived from an E. coli K12 genomic clone bank (Karn et al., Proc. Nat' 1. Acad. Sci., 77, 9: 5172-5176 (1980); clone bank obtained from M. Eenedik, Stanford University) was isolated, digested with BanHI restriction endonuclease and ligated into BamHI-digested pB3339 under conditions favoring the formation of hybrid molecules. E. coli serine auxotroph G3004 was then transformed to Kanr and serine independence using aliquots of the hybrid molecules. Plasmid pGM3147 was isolated as a serine independent Kanr, tets transformant of G3004.
B. Construction of serC-Containing Donor Plasmid A nucleotide sequence ( λ) 1059 serC) derived from an E. coli K12 genomic clone bank (supra) was isolated, digested with Ncol restriction endonuclease and ligated into Ncol-digested pACYC184 under conditions favoring formation of hybrid molecules. E. coli serine auxotroph CGSC #4297 (K.B. Low via B. Bachmann) was transformed to tetr and serine independence using aliquots of the hybrid molecules. Plaanid pGM3134 was isolated as a serine independent tetr transformant of CGSC #4297.
C. Construction of pGM3207 From Donor Plasmids
Plasmid pGM3134 was digested with Bglll and Xhol restriction endonucleases, to yield a 5.3 kb Bglll-Xhol fragment containing serC.
A sanple of plaanid pGM3147 was digested with Bglll and Sall restriction endonucleases to yield a 9.9 kb Bglll-Sall fragment containing serB and a gene specifying kanamycin resistance.
The pGM3134 5.3 kb Bglll-Xhol fragment was ligated to the pGM31479.9 kb Bglll-Sall fragment with T4 ligase. The products of this ligation mixture were used to transform CGSC #4297 (serC auxotroph) to Kanr, Ser+. Plaanid DNA purified from one of these transformants was used to transform G3004 (CGSC #5409 derivative and serB auxotroph, see above in Section A) to Kanr, Ser+. The transforming plaanid was designated pGM3207. Construction of Host Strain B1238 [W3110 F- (argF-lac)Δ U1 69, Δ(gal-bio), ∅ (trp-lac) W205, ∅(trp-Δ 61-intc-226), trpR] (Benedik et al., Gene, 19:303-311 (1982)) was transduced to Gal+ with P1 phage grown on strain W3110. The resulting strain designated S1238GB was subjected to ethyl methane sulfonate mutagenesis and was plated on glucose minimal median containing 2000 mg/l anthranilate. One anthranilate resistant colony was selected and was designated A103.
A103 was transduced to tetracycline resistance with a P1 lysate of E. coli strain TST 1 (T.J. Silhavy via B. Bachmann). TST 1 is known to carry a Tn10 insertion in the malE gene (malE52:Tn10) which is closely linked to the gene ceding for phosphoglucose isomerase (pgi). Tetr colonies were selected on LB agar median with 10 mg/l tetracycline and one of these was designated A103T. A nunber of spontaneously-occurring fusaric acid resistant derivatives of A103T were isolated on fusaric acid plates. Fusaric acid resistant isolates were screened on glucose tetrazolion plates and those isolates which formed white colonies on this medium were tested further. One of these was found to be auxotrophic for lysine in the presence of methionine and threonine. Since the genes lysC and malE flank the pgi gene it was assumed that the lysine auxotroph had a complete deletion of the pgi locus. This isolate was designated CT10 and was assumed to be ( lysC-pgi-malE)Δ .
A derivative of CT10 which was additionally deficient in the activity of tryptophanase (tna), was made by P1 transduction of CT10 to Sal+ (growth on salicin plates) with lysates of strain C537. These transductants were screened for tryptophanase activity and one Tna- isolate was selected and named C536. C537 mentioned above had been constructed by P1 transduction of MV17 (D. Helinski to Sal+ using lysates of E. coli strain N1624 (M. Gottesman via B. Bachmann) and selecting one transductant that was still Tna-. C534, a Tna- derivative of A103, was constructed in a manner analogous to that described above for C536.
Strain D2307, which carries a mutation in the tyrR gene ceding for tyrosine repressor which controls the prcduction of shikimate kinase, was made bv P1 transduction of E. coli strain JP2144F (A.J. Pittard via B. Bachmann) to Trp+ with lysates of E. coli strain W3110. D2307 was picked as a 3-fluorotyrosine resistant strain on minimal median containing 3-fluorotyrosine.
Strain D2316, a strain deficient in the prcduction of phenylalanine caused by a deficiency in the pheA gene which cedes for the first enzyme of the phenylalanine biosynthetic pathway, was made by conjugation of strain C536 and strain KA197 (H. Qkestra via B. Bachmann). D2316 was selected as a Trp+ phenylalanine auxotrophic transconjugant by replica plating on median either containing or lacking phenylalanine.
Strain D2139 was made by P1 transduction of strain MV17 (D. Helsinki, supra) with lysates of MB82 (Benedik et al. Virology, 126:658668 (1983)). Strain D2316 was made Tetr by P1 transduction with lysates of strain D2139, which contains a Tn10 insertion in the trpB gene (trpB::Tn10). A Tetr Trp- transductant was isolated and designated D2317. D2317 was PI transduced to 3-fluorotyrosine resistance with lysates of D2307 described above. D2318 characterized as tryptophan independent, 3-fluorotyrosine resistant and phenylalanine-requiring was one of the transductants obtained.
D2318 was P1 transduced using lysates of strain AT2471 (A.L. Taylor via B. bachmann), a tyrA mutant strain. Phenylalanine-independent colonies were selected by growth on median containing tryosine but lacking phenylalanine. Phenylalanine-independent colonies were screened for tyrosine dependence and a Phe+Tyr- strain was isolated and designated D2320.
A strain having feedback resistant anthranilate synthetase was constructed from strain D2320 by first making D2320 Tetr by P1 transduction with lysates of D2319. The trpB::Tn10 sequence was introduced into D2320 in a manner analogous to that used in making D2317. One Tetr transductant (D2324) was P1-transduced using lysates of a spontaneously occurring derivative of W3110 having anthranilate synthetase resistant to feedback inhibition by tryptoph.an. A tryptophan independent, 7-methyltryptoρhanresistant transductant that was auxotrophic for tyrosine and sensitive to tetracycline was selected and designated D2325. Enzyme assays (according to Ito and Crawford, Genetics, 52: 1303-1316 (1965)) in the presence of 2 mM L-tryptophan confirmed that D2325 specified a feedback-resistant anthranilate synthetase.
A strain designated D2327 which is auxotropic for phenylalanine and tyrosine independent was made by P1 transduction of D2325 to Tyr+ using lysates of strain KA197. (Hoekstra via B. Bachmann).
Strain D2327 was made Tetr by P1 transduction with lysates of an E. coli strain (C541) having a Tn10 insertion in the nadA locus and an adjacent deletion removing nadA, aroG, gal. C541 was made by P1 transduction of MV17 (D. Helsinki, supra) with lysates of strain C531. The Tetr derivative of D2327 was then transduced using P1 lysates of strain MAR13 (Held and Smith, supra). Marl 3 carries an arcmatic anino acid feedback resistant DAHP synthetase activity. Transduced cells were isolated as Nad+, Phe-, tetracycline sensitive strains. In one transductant, feedback resistance of DAHP synthetase to phenylalanine was determined by enzyme assay in the presence of 1 mM phenylalanine. This strain was designated D2346. A phenylalanine independent strain of D2346 was made by P1 transduction of D2346 using lysates of AT2471 (A.L. Taylor, supra) and selecting for phenylalanine independence on median containing tyrosine. One Phe+Tyr- transductant was designated D2402.
B1364 is a trp+lac+ transductant of B1363 (Mascarenhas et al., Virology, 124:100-108, (1983)) using P1 lysates of W3110. B1364 thus has genetic information for β-galactosidase, lactose transacetylase, and lactose permease activity all fused to and under the control of the tryptophan operon (∅ trp-lac W205). Strain D2402 was made Tetr by P1 transduction using a lysate of D2139 as above; a Tetr derivative of D2402 was then transduced to Trp+ac+ with P1 lysates of strain B1364. One Trp+Lac+Tets 7-methyl-tryptophan resistant (7MTr) isolate was designated D2432.
D2432 was made Tetr by P1 transduction using P1 lysates of strain RS162 (J. Wechsler via B. Bachnann) . The resulting Tetr strain (D2548) has a Tn10 insertion in the zjb locus and a temperature sensitive mutation dnaB252. A spontaneous isolate of this strain capable of utilizing hydroxyphenyl pyruvate was isolated and designated D2549. D2549 was P1-transduced using lysates of strain EG30 (D, Gelfand via B. Bachmann), a strain lacking transaninase A (tyrB-). Transductants were isolated by growth on LB agar at 42°C (loss of dnaB252 mutation) and screened for inability to grow on plates containing p-hydroxyphenylpyruvate. One such isolate was designated D2550.
A spontaneous tetracycline sensitive (fusaric acid resistant) derivative of D2550 designated D2618 was selected on fusaric acid plates. D2618 was then made Tetr by P1 transduction using lysates of NK6024 (N. Kleckner via B. Bachmann), a strain having a Tn10 insertion in the pheA locus. Tetracycline resistant colonies were selected and one Phe-Tyr- transductant was designated D2636. Spontaneous fusaric acid resistant (Tets) derivatives of D2636 were selected on fusaric acid plates and checked for phenylalanine and tyrosine requirements. One such isolate (Phe-Tyr-Tets) was designated D2637.
D2637 was transduced to Tetr (Ser-) using P1 lysates of strain 123A1, which contain a Tn10 insertion linked to the serC locus in strain strain KL282 (K. B. Low via B. Bachmann). One TetrSer- transductant, designated D2638, was transduced to Ser+ with P1 lysates from DG30 (D. Gelfand via B. Bachmann) which contains an aspC mutation and is auxotrophic for aspartic acid. These transductants were screened for aspartic acid auxotrophy. One aspartic acid auxotroph that was serine independent and TetS was designated D2639.
Serine deaninase-deficient derivatives of D2637 were constructed as follows: Strain MEW191 and a P1-sensitive derivative of strain 1K15-5 (both strains received from E. Newman, Concordia University) are believed to carry mudX ( Cam,Amp) insertions in regulatory and structural genes for L-serine deaminase, respectively. A P1 lysate of each of these strains was used to transduce D2637 to CamrMpr. Single transductants from each cross were designated D2711 and D2713 respectively, and were deemed to carry the mudX (Cam, Mp) insertions (regulatory:D2711, structural:D2713) present in their respective parents. Spontaneous CamSAmps derivatives of D271 1 and D271 3 were isolated and designated D2714 and D2715 respectively. Enzyme assays confirmed that both D2714 and D2715 were deficient in L-serine deaminase activity.
Improved Tryptophan prcduction in Pgi- host compared to Isogenic Pgi+ host C534 and C536 are isogenic E. coli strains except that the pgi gene has been deleted in C536. C534 was made by PI transduction of A103 using lysates grown on C537 and screening for Tna- colonies. C536 was described above. These strains were cured of their resident plasmids by isolation of Amps segregants in each case. These cured derivatives were then transduced to TetR with P 1 grown on D2636 (tyrA4 pheA18: :Tn10 ) . Single transductants were then cured of the transposon by selection of spontaneous fusaric-acid-resistant segregants on fusaric acid plates. One of these, D2704, was Pgi+Tyr-Phe-Tets (derived from C534 ) . D2705, which is Pgi-, was derived from C536 in a way similar to D2704 and is otherwise isogenic to D2704.
D2704 and D2705 were each transformed sequentially with pD2634, pD2643 and pD2625 - by selection for Amp R, TetR and CamR, respectively, using conventional calcium shock to render the host competent for transformation. These plasmids carry the genes for the key enzymes of tryptophan biosynthesis and were described hereinafccve. One triple transformant in each case was used for nuclear magnetic resonance (NMR) analysis.
13C-glucose NMR spectroscopy of D2704 and D2705 derivatives
Single colonies of each strain were inoculated into minimal median (5 mis) containing 1 . 5% glucose, 0. 4% NZ-amine, 10mM M g SO4, 1 ug/ml each FeSO4 and MnSO4, and anpicillin, tetracycline and chloranphenicol. These cultures were grown overnight at 37 °C, then diluted 1 : 12 into the sane median plus 1 mM isopropyl- β -D-thicgalactopyranoside (IPTG) and 0.5% w/V 13C-glucose ( labelled in the C6 position) . This culture was transferred to an NMR tube and used directly for N MR spectroscopy at 28 °C using a Varion Associates XL200 NMR spectrcmetry system. Aeration of the culture was achieved by rotating the tube and pumping air through the culture during the run. Spectra were acquired at 3-hour intervvls. Analysis of results
Table II summarizes the efficiency of conversion of glucose to tryptophan by the strains described immediately above. Fran the intensity of the peaks of the NMR spectra corresponding to C6-glucose and C6-tryptophan, one can calculate the increase in tryptophan relative to the decrease in glucose (after making allowance for the molecular weights of the two compounds).
The results suggest that the pgi block in D2705 serves to substantially increase efficiency of conversion of glucose to tryptophan, when compared to D2704.
*Correction factor 1.133 applied for molecular weight difference
Effect of Chromosomal Mutations on Tryptophan Production Twenty milliliter cultures of the strains listed in Table III below were grown in side-arm flasks at 30°C on a rotary shaker at 280 rpm. The growth median was MINIMAL MEDIt-M #3 described hereinabove supplemented with 1% gluccse and 0.4% casamino acids (Difco). Culture supernatants were assayed for tryptophan after 3 days, by the method of Spies and Chamber (Anal. Chem. 20:30, 1947). w.t. = wild type;
* all strains are derivatives of W3110F- and carry, in addition, the following markers: (argF-lac) U169, tna 2, bglR6, (lysC-pgi-malE) trpR, (anthranilate-resistance)
Effect of Transaninase A activity on Tryptophan Accumulation Cultures used in Table IV were grown and assayed exactly as described in the legend to Table III except that the growth median was MINIMAL MEDKSM supplanented with 2% glucose, 1% NZ-amine, 1mM IPTG, chloranphenicol (20 mg per ml) and ampicillin (100 mg per ml).
** These strains also carry the following markers: (argF-lac) U169, arcGFBR, ∅(trp-lac) W205, trpEfbr31, tyrR366, tyrA4, tna2, bglR6, (lysC-pgi-malE) , trpR, (anthranilate-resistance).
Effect of Plasmid Genes on Tryptophan Prcduction Fifty milliliter cultures of the strains listed in Table V below were grown in 500 ml baffled flasks, in triplicate, for 44 hours on a rotary shaker (280 rpm) at 30ºC. The growth mediun was MINIMAL MEDIUM supplanented with 5% glucose, 1% NZ-amine, 1mM IPTG, tetracycline (5mg/ ml), ampicillin (100 mg/ml) and chloranphenicol (20 mg/ml). Culture supematants were assayed by the method of Spies and Chanber (Anal. Cham. 20: 30, 1947). The genotype of the host strain, D2618, is as follows: W3110 F-( argF-lac) U169, aroGPBR, ∅ (trp-lac) W205, trpEFBR31, tyrR366, tyrA4, tna2, bglR6, (lysC-pgi-malE) , tyrB507, zjb, trpR, (anthranilate-resistance).
Tryptophan Prcduction in Serine-Deaninase Deficient Strain
Cultures indicated in Table VI were grown and assayed exactly as described in the legend to Table V above except that the incubation period was 43 hours and each value is the average of 2 flasks only. D2715 is derived from D2618 by introducing deletions into the pheA gene and into the structural gene for serine deaminase.
Deposited Microorganisms
The following microorganisms have been deposited in the American Type Culture Collection.
Strain D2715 in which are cloned pD2625, pD2634, pD2643 and pGM3207 is not only deposited under ATCC Accession Number 53064 but is also deposited in a security deposit to which the United States Patent and Trademark Office has irrevocable access. (Security Deposit No. 799.)
It will be readily apparent that the inventor has provided, in addition to the unique bacterial hosts and plaanids, a method for increasing the production of tryptophan in a host of the strains of Escherichia, particularly E. coli. The general method according to the invention comprises the steps of transforming an E . coli host deficient in tryptophanase with plasmid-borne genetic information to control tryptophan prcduction divided between at least two plaanids, growing the transformed host in an appropriate nutrient median for a period of time sufficient to produce tryptophan as exemplified above, and producing tryptophan by the transformed host. Tryptophan from the culture broth may be removed by any conventional technique. The tryptophan so obtained may be further refined or purified as desired. Preferably the host, in addition to being Tna-, will be deficient in the activity of phosphoglucose isomerase (pgi-). The host, in addition to or instead of being pgi-, may also have DAHP synthetase activity resistant to aromatic anirio acid inhibition, anthranilate synthetase activity resistant to tryptophan innibition, deficiencies in the activity of lac repressor, aromatic transaminase A, L-serine deaninase either singly or in any combinations thereof.
The inventor has also provided a method for increasing the production of tryptophan in a host of the genus Escherichia, particularly E. coli by transforming an E.coli host deficient in the enzyme tryptophanase with a plaanid carrying plaanid-borne genetic information to control tryptophan production, a portion of said information including lac operator/promoter control, growing the transformed host in an appropriate median as exemplified above and prcducing tryptophan by the transformed host.
Preferably the E. coli host will have the additional characteristics described above with respect to pgi-, DAHP synthetase, anthranilate synthesis, lac repressor activity, aromatic transaminase and L-serine deaminase.
In a most preferred embodiment, the preferred E. coli host is transformed with plasmid-borne genetic information to control tryptophan production divided between at least two plaanids, a portion of the information to control tryptophan prcduction being under lac operator/promoter control.
The foregoiηg description of the invention is intended to provide a guide, to those ordinarily skilled in the arts to which the invention pertains, to the means to attain and practice the invention as claimed hereinbelow. It will be readily apparent to those ordinarily skilled in the art to which the invention pertains that one may depart from the exact description of the invention contained herein without departing from the scope of the invention as claimed.

Claims

WHAT IS CLAIMED IS:
1. A bacterium comprising a host of the genus Escherichia deficient in the enzyme tryptophanase carrying plasmid-borne genetic information to control tryptophan production divided between at least two replication-compatible plaanids.
2. A bacterium comprising a host of the genus Escherichia deficient in the enzyme tryptophanase carrying plasnid-borne genetic information to control tryptophan prcduction divided between at least two plaanids , a portion of said information under lac operator/promoter control.
3. The bacteriun of Claim 2 having information to control serine biosynthesis including serA, serB and/or serC not under lac operator/promoter control.
4. The bacterium of Claim 1 wherein at least one of said plaanids carries information controlling biosynthesis of the common precursors of the aromatic amino acids.
5. The bacterium of Claim 4 wherein at least one of said plasmids carries genetic information for DAHP synthetase activity resistant to inhibition by aromatic amino acids under lac promoter control.
6. The bacterium of Claim 2 wherein said plasmid borne genetic information for control of tryptophan prcduction includes trpA-E genes wherein trpA-D are under lac operator/promoter control , said plasmid carries a deletion in the trp attenuator region and wherein trpE cedes for anthranilate synthetase resistant to inhibition by tryptophan.
7. The bacteriun of Claim 2 wherein said plasmid-borne genetic information further includes a region for constitutively produced lac repressor activity.
8. The bacterium of Claim 2 wherein said host additionally has activities selected from the group consisting of DAHP synthetase resistant to aromatic anino acid inhibition, anthranilate synthetase resistant to tryptophan inhibition, deficiency in activity of: lac repressor ; phosphoglucose isomerase ; arcmatic transaminase A; L-serine deaminase ; tyrA; pheA; trpR and combinations thereof.
9. A method for the production of tryptophan comprising growing the bacteriαn of Claim 1 in an appropriate culture medium for a period of time suitable to produce tryptophan, and raneving said tryptophan from the culture medium.
10. A method for increasing the production of tryptophan by an E. coli bacterium comprising transforming the host of Claim 1 with at least two plaanids, said plasmids being divided therebetween genetic information to control tryptophan prcduction, and growing said transformed host in culture median appropriate for tryptophan production by said transformed host.
EP19850904319 1985-08-15 1985-08-15 Tryptophan producing microorganism. Withdrawn EP0232262A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1985/001542 WO1987001130A1 (en) 1985-08-15 1985-08-15 Tryptophan producing microorganism

Publications (2)

Publication Number Publication Date
EP0232262A1 true EP0232262A1 (en) 1987-08-19
EP0232262A4 EP0232262A4 (en) 1989-09-19

Family

ID=22188804

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19850904319 Withdrawn EP0232262A4 (en) 1985-08-15 1985-08-15 Tryptophan producing microorganism.

Country Status (2)

Country Link
EP (1) EP0232262A4 (en)
WO (1) WO1987001130A1 (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047538A1 (en) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO2002016625A2 (en) 2000-08-25 2002-02-28 Basf Plant Science Gmbh Plant polynucleotides encoding prenyl proteases
EP1683865A2 (en) 2001-02-02 2006-07-26 Eli Lilly & Company Mammalian proteins and in particular CD200
WO2007056352A2 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
WO2007084631A2 (en) 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2007124464A2 (en) 2006-04-20 2007-11-01 Becton, Dickinson And Company Thermostable proteins and methods of making and using thereof
WO2008105797A2 (en) 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucleotides encoding novel pcsk9 variants
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
EP2025682A2 (en) 1996-08-16 2009-02-18 Human Genome Sciences, Inc. Human endokine alpha
WO2009041501A1 (en) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. Factor involved in latent infection with herpesvirus, and use thereof
EP2055718A1 (en) 2005-11-11 2009-05-06 Ludwig-Maximilians-Universität München Targeting and tracing of antigens in living cells
EP2065396A1 (en) 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
EP2080766A1 (en) 2001-06-06 2009-07-22 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides useful for immunomodulation
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
WO2010093928A2 (en) 2009-02-12 2010-08-19 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
EP2228389A2 (en) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
EP2264174A2 (en) 1998-07-22 2010-12-22 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding CDNA
EP2287339A1 (en) 2004-05-18 2011-02-23 Georg Dewald Methods and kits to detect hereditary angioedema type III
EP2287310A1 (en) 2004-07-22 2011-02-23 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
EP2290080A2 (en) 2000-11-28 2011-03-02 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
EP2301969A1 (en) 2005-05-06 2011-03-30 ZymoGenetics, L.L.C. IL-31 monoclonal antibodies and methods of use
EP2332961A2 (en) 2001-10-11 2011-06-15 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2332975A1 (en) 1997-05-30 2011-06-15 Human Genome Sciences, Inc. Human proteins
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
WO2012009631A1 (en) 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
EP2431054A2 (en) 2000-06-15 2012-03-21 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP2471817A2 (en) 2007-12-07 2012-07-04 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
WO2013033680A1 (en) 2011-09-02 2013-03-07 Lifenet Health Bmp peptides & methods of use
EP2594586A1 (en) 2006-09-01 2013-05-22 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
WO2013174003A1 (en) 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
EP2685260A1 (en) 2012-07-09 2014-01-15 Ludwig-Maximilians-Universität München Direct and quantitative detection of targets in living cells
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
WO2016040488A2 (en) 2014-09-10 2016-03-17 Georgetown University Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
EP3023502A1 (en) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2016081728A1 (en) 2014-11-19 2016-05-26 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
EP3031470A2 (en) 2005-09-09 2016-06-15 The Johns Hopkins University Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
EP3072963A1 (en) 2007-10-18 2016-09-28 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP3181588A1 (en) 2008-01-11 2017-06-21 Adheron Therapeutics, Inc. Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
WO2020185763A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
EP4400174A2 (en) 2017-09-01 2024-07-17 The Francis Crick Institute Limited Immunoregulatory molecules and uses therefor

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0746994B2 (en) * 1984-10-04 1995-05-24 味の素株式会社 Method for producing L-amino acid by fermentation method
EP0245497A4 (en) * 1985-11-12 1989-06-27 American Biogenetics Corp Biogenetic cassette.
JP2967996B2 (en) * 1989-06-06 1999-10-25 協和醗酵工業株式会社 Method for producing L-tryptophan
DE4232468A1 (en) * 1992-09-28 1994-03-31 Consortium Elektrochem Ind Microorganisms for the production of tryptophan and process for their production
DE69637492T2 (en) 1995-05-05 2009-06-04 Genencor International, Inc., Palo Alto Use of glucose transport mutants for the preparation of compounds of the aromatic synthesis pathway
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US5939295A (en) * 1996-03-29 1999-08-17 Archer Daniels Midland Company Production of tryptophan by microorganisms
AU2023499A (en) 1998-12-31 2000-07-24 General Hospital Corporation, The Pth receptor and screening assay utilizing the same
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
US8372989B2 (en) 2002-04-23 2013-02-12 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of monatin and its precursors
US7572607B2 (en) 2002-04-23 2009-08-11 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of monatin and its precursors
PL208481B1 (en) 2002-04-23 2011-05-31 Cargill Method for monatin production
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US20050079617A1 (en) 2003-10-03 2005-04-14 Cervin Marguerite A. Glucose transport mutants for production of biomaterial
WO2004033421A2 (en) 2002-10-04 2004-04-22 Genencor International, Inc. Improved production of bacterial strains
WO2005014839A2 (en) 2003-08-01 2005-02-17 Cargill, Incorporated Monatin tabletop sweetener compositions and methods of making same
ATE498691T1 (en) 2003-10-21 2011-03-15 Cargill Inc PRODUCTION OF MONATIN AND MONATIN PRECURSORS
CN101223444B (en) 2005-04-20 2013-04-24 嘉吉有限公司 Methods for in vivo secretion of monatin
US8158389B2 (en) 2005-04-20 2012-04-17 Cargill, Incorporated Products and methods for in vivo secretion of monatin
DE102005018835A1 (en) 2005-04-22 2006-11-02 Degussa Ag Process for the preparation of L-amino acids using improved strains of the family Enterobacteriaceae
DE102005019040A1 (en) 2005-04-23 2006-10-26 Degussa Ag Process for the preparation of L-amino acids using improved strains of the family Enterobacteriaceae
US8076108B2 (en) 2005-04-26 2011-12-13 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
US7582455B2 (en) 2005-04-26 2009-09-01 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
KR100792095B1 (en) 2006-12-29 2008-01-04 씨제이 주식회사 - - genetically engineered l-tryptophan producing recombinant escherichia coli which has originally l-phenylalanine production character and the method for producing l-tryptophan using the microorganism
DE102007051024A1 (en) 2007-03-05 2008-09-11 Evonik Degussa Gmbh Process for the preparation of L-amino acids using strains of the family Enterobacteriaceae
EP1975241A1 (en) 2007-03-29 2008-10-01 Evonik Degussa GmbH Method for manufacturing L-amino acids using improved strains of the enterobacteriaceae family
AU2008282805B2 (en) 2007-08-01 2014-05-01 Chugai Pharmaceutical Co., Ltd. Screening methods using G-protein coupled receptors and related compositions
DE102007044134A1 (en) 2007-09-15 2009-03-19 Evonik Degussa Gmbh Process for the preparation of L-amino acids using improved strains of the family Enterobacteriaceae
DE102007052270A1 (en) 2007-11-02 2009-05-07 Evonik Degussa Gmbh Process for the preparation of L-amino acids using improved strains of the family Enterobacteriaceae
EP2060636A1 (en) 2007-11-14 2009-05-20 Evonik Degussa GmbH Method for manufacturing L-amino acids using improved strains of the enterobacteriaceae family
EP2098597A1 (en) 2008-03-04 2009-09-09 Evonik Degussa GmbH Method for manufacturing L-amino acids using improved strains of the enterobacteriaceae family
DE102008002309A1 (en) 2008-06-09 2009-12-10 Evonik Degussa Gmbh Process for the preparation of L-amino acids using improved strains of the family Enterobacteriaceae
DE102008040352A1 (en) 2008-07-11 2010-01-14 Evonik Degussa Gmbh Process for the preparation of L-tryptophan using improved strains of the family Enterobacteriaceae
DE102008044768A1 (en) 2008-08-28 2010-03-04 Evonik Degussa Gmbh Process for the preparation of organochemical compounds using improved strains of the family Enterobacteriaceae
RU2604809C2 (en) 2010-05-13 2016-12-10 Дзе Дженерал Хоспитал Корпорейшн Parathyroid hormone analogs and uses thereof
SI3246044T2 (en) 2010-08-23 2024-06-28 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
ES2585328T5 (en) 2010-09-10 2022-12-14 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
HUE057864T2 (en) * 2012-01-10 2022-06-28 Cj Cheiljedang Corp Microorganisms of escherichia coli having enhanced l-tryptophan production and method for producing l-tryptophan using same
EP2628792A1 (en) 2012-02-17 2013-08-21 Evonik Industries AG Cell with reduced ppGppase activity
RU2665841C2 (en) 2012-03-09 2018-09-04 Пфайзер Инк. Neisseria meningitidis compositions and methods of use thereof
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
EP2762571A1 (en) 2013-01-30 2014-08-06 Evonik Industries AG Microorganism and method for the production of amino acids by fermentation
JP6446377B2 (en) 2013-03-08 2018-12-26 ファイザー・インク Immunogenic fusion polypeptide
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RU2723045C2 (en) 2015-02-19 2020-06-08 Пфайзер Инк. Compositions of neisseria meningitidis and methods for preparation thereof
IL267733B2 (en) 2017-01-31 2023-10-01 Pfizer Neisseria meningitidis compositions and methods thereof
EP3385275B1 (en) 2017-04-07 2019-10-23 Evonik Degussa GmbH Method for producing aromatic l-amino acids using improved strains of the enterobacteriaceae family
US11053526B2 (en) 2018-08-09 2021-07-06 Evonik Operations Gmbh Process for preparing L amino acids using improved strains of the enterobacteriaceae family
CN113677795B (en) * 2019-04-10 2024-04-23 曾安平 Novel DAHP synthetase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124048A2 (en) * 1983-04-23 1984-11-07 Ajinomoto Co., Inc. Method for producing L-tryptophan by fermentation
EP0145156A1 (en) * 1983-10-07 1985-06-19 Biotechnica International, Inc. Expression vectors, host cells comprising such vectors and methods of making desired compounds using such cells
EP0149539A2 (en) * 1984-01-13 1985-07-24 Stauffer Chemical Company Mutant strains deficient in L-serine deaminase activity and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371614A (en) * 1980-08-22 1983-02-01 Ajinomoto Co., Inc. E.Coli bacteria carrying recombinant plasmids and their use in the fermentative production of L-tryptophan
EP0077196A3 (en) * 1981-10-09 1984-06-06 Genex Corporation Aromatic amino acid-producing microorganisms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124048A2 (en) * 1983-04-23 1984-11-07 Ajinomoto Co., Inc. Method for producing L-tryptophan by fermentation
EP0145156A1 (en) * 1983-10-07 1985-06-19 Biotechnica International, Inc. Expression vectors, host cells comprising such vectors and methods of making desired compounds using such cells
EP0149539A2 (en) * 1984-01-13 1985-07-24 Stauffer Chemical Company Mutant strains deficient in L-serine deaminase activity and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8701130A1 *

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025682A2 (en) 1996-08-16 2009-02-18 Human Genome Sciences, Inc. Human endokine alpha
EP2065396A1 (en) 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
EP2332975A1 (en) 1997-05-30 2011-06-15 Human Genome Sciences, Inc. Human proteins
WO1999047538A1 (en) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP1982990A1 (en) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP2264174A2 (en) 1998-07-22 2010-12-22 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding CDNA
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP2431054A2 (en) 2000-06-15 2012-03-21 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO2002016625A2 (en) 2000-08-25 2002-02-28 Basf Plant Science Gmbh Plant polynucleotides encoding prenyl proteases
EP2290080A2 (en) 2000-11-28 2011-03-02 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
EP1683865A2 (en) 2001-02-02 2006-07-26 Eli Lilly & Company Mammalian proteins and in particular CD200
EP2228389A2 (en) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
EP2080766A1 (en) 2001-06-06 2009-07-22 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides useful for immunomodulation
EP2348036A2 (en) 2001-10-11 2011-07-27 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2343308A2 (en) 2001-10-11 2011-07-13 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2371838A1 (en) 2001-10-11 2011-10-05 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP3199539A1 (en) 2001-10-11 2017-08-02 Wyeth Holdings LLC Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2332961A2 (en) 2001-10-11 2011-06-15 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2348034A2 (en) 2001-10-11 2011-07-27 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2348035A2 (en) 2001-10-11 2011-07-27 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2371836A1 (en) 2001-10-11 2011-10-05 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2366707A1 (en) 2001-10-11 2011-09-21 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2351767A2 (en) 2001-10-11 2011-08-03 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2371837A1 (en) 2001-10-11 2011-10-05 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2341063A2 (en) 2001-10-11 2011-07-06 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2341062A2 (en) 2001-10-11 2011-07-06 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP3056571A1 (en) 2004-05-18 2016-08-17 Georg Dewald Methods and kits to detect hereditary angioedema type iii
EP2287339A1 (en) 2004-05-18 2011-02-23 Georg Dewald Methods and kits to detect hereditary angioedema type III
EP2287310A1 (en) 2004-07-22 2011-02-23 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
EP2479277A2 (en) 2004-07-22 2012-07-25 Five Prime Therapeutics, Inc. Compositions and methods of use for MGD-CSF in disease treatment
EP2301969A1 (en) 2005-05-06 2011-03-30 ZymoGenetics, L.L.C. IL-31 monoclonal antibodies and methods of use
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
EP3031470A2 (en) 2005-09-09 2016-06-15 The Johns Hopkins University Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
WO2007056352A2 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
EP2055718A1 (en) 2005-11-11 2009-05-06 Ludwig-Maximilians-Universität München Targeting and tracing of antigens in living cells
EP2671954A2 (en) 2006-01-20 2013-12-11 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
EP3936621A1 (en) 2006-01-20 2022-01-12 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP3360965A1 (en) 2006-01-20 2018-08-15 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2007084631A2 (en) 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2007124464A2 (en) 2006-04-20 2007-11-01 Becton, Dickinson And Company Thermostable proteins and methods of making and using thereof
EP2671946A1 (en) 2006-06-30 2013-12-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2639301A2 (en) 2006-06-30 2013-09-18 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008105797A2 (en) 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucleotides encoding novel pcsk9 variants
EP2594586A1 (en) 2006-09-01 2013-05-22 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
EP2759549A2 (en) 2006-09-01 2014-07-30 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
EP2987859A1 (en) 2007-09-27 2016-02-24 Japan Tobacco Inc Factor involved in latent infection with herpesvirus, and use thereof
WO2009041501A1 (en) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. Factor involved in latent infection with herpesvirus, and use thereof
EP3741851A1 (en) 2007-10-18 2020-11-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP3072963A1 (en) 2007-10-18 2016-09-28 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP2471817A2 (en) 2007-12-07 2012-07-04 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
EP2796466A2 (en) 2007-12-07 2014-10-29 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
EP3181588A1 (en) 2008-01-11 2017-06-21 Adheron Therapeutics, Inc. Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
EP3023502A1 (en) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
EP2881402A1 (en) 2009-02-12 2015-06-10 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
WO2010093928A2 (en) 2009-02-12 2010-08-19 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
EP3266795A1 (en) 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Method for detecting a fig-ros fusion polynucleotide
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
EP3345925A2 (en) 2010-07-15 2018-07-11 Adheron Therapeutics, Inc. Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
WO2012009631A1 (en) 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
WO2013033680A1 (en) 2011-09-02 2013-03-07 Lifenet Health Bmp peptides & methods of use
EP3508497A1 (en) 2012-05-24 2019-07-10 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
US9290564B2 (en) 2012-05-24 2016-03-22 Mountgate Group Limited Compositions and methods related to the prevention and treatment of rabies infection
WO2013174003A1 (en) 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
EP2685260A1 (en) 2012-07-09 2014-01-15 Ludwig-Maximilians-Universität München Direct and quantitative detection of targets in living cells
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
WO2016040488A2 (en) 2014-09-10 2016-03-17 Georgetown University Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
WO2016081728A1 (en) 2014-11-19 2016-05-26 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
EP4400174A2 (en) 2017-09-01 2024-07-17 The Francis Crick Institute Limited Immunoregulatory molecules and uses therefor
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
WO2020185763A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate

Also Published As

Publication number Publication date
EP0232262A4 (en) 1989-09-19
WO1987001130A1 (en) 1987-02-26

Similar Documents

Publication Publication Date Title
EP0232262A1 (en) Tryptophan producing microorganism
US5658766A (en) Strains of Escherichia coli which produce isoleucine or valine and a method for their production
US4371614A (en) E.Coli bacteria carrying recombinant plasmids and their use in the fermentative production of L-tryptophan
EP0763127B1 (en) Deblocking the common pathway of aromatic amino acid synthesis
US4407952A (en) Method for producing L-phenylalanine by fermentation
US6962794B2 (en) Application of glucose transport mutants for production of aromatic pathway compounds
US6960455B2 (en) Methods of making amino acids using E. coli transformed with csc genes
EP0030727B1 (en) Method for producing l-valine by fermentation and method for producing a new microorganism of the genus escherichia
US4430430A (en) Method for producing L-arginine by fermentation
EP0789073A2 (en) Production of tryptophan by the bacterium Escherichia coli
EP0136359A1 (en) Process for preparing l-histidine
GB2055805A (en) Preparation of l-histidine by fermentation
EP1322765A1 (en) Escherichia coli/ strains which over-produce l-threonine and processes for the production of l-threonine by fermentation
AU2001296415A1 (en) Escherichia coli strains which over-produce L-threonine and processes for the production of L-threonine by fermentation
JP2003506030A (en) Metabolic engineering of amino acid production
US5034318A (en) Method for producing L-tryptophan by fermentation
US5426050A (en) Plasmid vectors for expression of genes in coryneform bacteria
US4393135A (en) Method for producing L-glutamic acid by fermentation
EP0183006B1 (en) A recombinant dna-molecule, coryneform bacteria carrying recombinant dna and process for producing an aromatic amino acid by using the same
EP0519113A1 (en) Bacterial strains having high productivity of an amino acid and method of constructing these strains
JPH0755155B2 (en) Amino acid manufacturing method
US20080241898A1 (en) Application of Glucose Transport Mutants For Production Of Aromatic Pathway Compounds
EP0178744A2 (en) Shuttle vector
EP0293207A2 (en) Eschericia coli carrying recombinant plasmid for the production of tryptophan
JPH062052B2 (en) Genetically modified Escherichia coli and method for producing L-phenylalanine using the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19870806

A4 Supplementary search report drawn up and despatched

Effective date: 19890919

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19900716

R18W Application withdrawn (corrected)

Effective date: 19900716

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MASCARENHAS, DESMOND